Position statement: immunomodulator therapy for inflammatory Bowel disease.
Lavy
Alexandra
A
Department of Gastroenterology, Bnei Zion Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Chowers
Yehuda
Y
Odes
H Shmuel
HS
Eliakim
Rami
R
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D012449:Safety; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D016572:Cyclosporine; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate